It is worth noting that the presence of amplifications of tyrosine kinase receptor genes or cell cycle mediators, characteristic of stable TP53-mutated GC, along with other frequently observed alterations among GC subtypes such as PIK3CA mutation, holds potential therapeutic value. Here, NTRK1 is linked to gastric cancer.